ClinicalTrials.gg
RecruitingNCT07010835Updated Feb 5, 2026

Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus

A Phase 1/2 interventional study of YK012 in Systemic Lupus Erythematosus (SLE), sponsored by Excyte Biopharma Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by Excyte Biopharma Ltd · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
189
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.

Planned enrollment
46th of 245
189 · median 36
Started
2025
with 61 others
Phase 1/2
19 of 266
13 open now
Primary completion
2027-06
later than 103 of 190 live
Registered
179th of 266
by date

Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 46th largest by planned enrollment of the 245 interventional ones that give a count, is one of 62 that started in 2025, is one of 19 in phase 1/2, reaches primary completion later than 103 of the 190 other live ones, and was the 179th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Lupus Erythematosus, Systemic with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of YK012 in participants with Moderate to Severe Systemic Lupus Erythematosus (SLE).

Read the detailed description

This clinical trial consists of Phase Ib and Phase II. Phase Ib consists of dose escalation stage and dose expansion stage. The main goal of dose escalation stage is to evaluate the safety and tolerability of YK012 in participants with Moderate to Severe Systemic Lupus Erythematosus (SLE), and the main goal of dose expansion stage is to evaluate the safety, tolerability and effectiveness in reducing disease activity of YK012 in participants with SLE. The main goal of phase II is to assess the efficacy of YK012 in participants with Moderate to Severe SLE. Pharmacokinetics, pharmacodynamics and immunogenicity of YK012 in participants are evaluated as secondary objectives in both phases.

03

Conditions studied

  • Systemic Lupus Erythematosus (SLE)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 75 years (inclusive) at screening, regardless of sex
  • Meet the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for SLE, with a confirmed SLE diagnosis for at least 24 weeks at screening
  • Positive for anti-dsDNA antibody and/or antinuclear antibody (ANA) and/or anti-Smith antibody at screening, as determined using the local laboratory's reference ranges at the study site
  • Medium to high disease activity at screening, defined as: Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score ≥7
  • Receiving stable background therapy at screening
  • Capable of understanding and voluntarily participating in this clinical trial, having provided written , and able to comply with scheduled visits, treatments, examinations, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  • Known allergy to monoclonal antibodies or exogenous human immunoglobulins, or to the drug or any of its components
  • Received any anti-CD19/CD20 therapy or any B-cell depleting agents within 6 months prior to enrollment, or B-cell stimulatory factor inhibitors within 3 months or 5 half-lives prior to enrollment
  • Received TNF inhibitors, interleukin receptor blockers, other small molecules or biologics within 3 months or 5 half-lives prior to enrollment
  • Received intravenous immunoglobulins or plasmapheresis within 3 months prior to enrollment
  • Used traditional Chinese medicines/herbal preparations for SLE treatment containing within 2 weeks prior to enrollment
  • Received live or attenuated vaccines within 1 month prior to enrollment
  • Has other diseases, inflammatory joint diseases, or skin disorders (other than SLE) that may interfere with disease activity assessment
  • History of within 5 years before screening, except for cured cases with no recurrence for at least 5 years, such as basal cell or squamous cell skin cancer, cervical carcinoma in situ, ductal carcinoma in situ of breast, or papillary thyroid cancer
  • cardiovascular/cerebrovascular diseases within 6 months prior to screening
  • Presence of interval prolongation on (ECG)
  • Presence of poorly controlled hypertension at screening
  • History of non-SLE conditions requiring oral/intravenous/intramuscular/subcutaneous therapy (>2 weeks) within 6 months prior to enrollment
  • Active tuberculosis at screening or untreated latent tuberculosis
  • History of solid organ or bone marrow transplantation
  • Presence of active infections
  • Lupus nephritis requiring protocol-prohibited medications as assessed by the investigator
  • Uncontrolled lupus crisis within 8 weeks prior to screening
  • History of central nervous system (CNS) disorders
  • Presence of clinically unstable or uncontrolled medical conditions at screening
  • Presence of clinically significant abnormal laboratory test results
  • Presence of active viral infections (e.g., , , , or active syphilis)
  • Had major surgery within 4 weeks prior to enrollment or planned during study;
  • Participation in other interventional clinical trials within 4 weeks prior to enrollment
  • Pregnant or lactating women, or individuals with pregnancy plans during the study and within a specified period after treatment who are unwilling to use effective
  • Other conditions deemed by investigators to preclude study participation.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
189 participants (estimated)

Study arms

  • Experimental
    YK012

    Phase Ib: Participants will receive four different target doses of YK012 in dose escalation stage to evaluate its safety and tolerability. Participants will receive two to three different target doses of YK012 in dose expansion stage to further evaluate its safety, tolerability and effectiveness in reducing disease activity. Phase II: Participants will receive either placebo or one to two different doses of YK012. The specific doses will be determined based on prior clinical trial results.

    Drug: YK012

Interventions

  • DrugYK012

    YK012 is a bispecific antibody targeting CD19 and CD3.

06

What researchers measure

Primary outcomes

  1. Ib dose escalation stage: Dose Limiting Toxicity (DLT)

    Time frame: From the first infusion of YK012 to Day 28 post first infusion

  2. Adverse Event (AE)

    An AE is defined as any untoward medical event that occurs after a participant receives the investigational drug, which may be manifested as symptoms, signs, diseases, or laboratory abnormalities, but may not necessarily have a causal relationship with the investigational drug.

    Time frame: From the first infusion of YK012 to the end of trial at 48 weeks

  3. Severe Adverse Event (SAE)

    An SAE refers to any untoward medical occurrence after the participant receives the IMP that results in one or more of the following: death, life-threatening event, permanent or serious disability or loss of function, hospitalization or prolongation of hospitalization, congenital abnormalities or birth defects.

    Time frame: From the first infusion of YK012 to the end of trial at 48 weeks

  4. Ib dose expansion stage and phase II: SRI-4 (Systemic Lupus Erythematosus Responder Index-4) response rates

    Time frame: From the first infusion of YK012 to the end of trial at 48 weeks

Secondary outcomes

  1. Area Under the Curve (AUC0-t) of a serum concentration versus time profile

    Time frame: From pre-dose of YK012 to the end of trial at 48 weeks

  2. Area under the blood concentration-time curve from zero to infinity (AUC0-∞)

    Time frame: From pre-dose of YK012 to the end of trial at 48 weeks

  3. Maximum Concentration (Cmax) of YK012

    Time frame: From pre-dose of YK012 to the end of trial at 48 weeks

  4. Time to Reach Cmax (Tmax)

    Time frame: From pre-dose of YK012 to the end of trial at 48 weeks

  5. Elimination Half Life (t1/2)

    Time frame: From pre-dose of YK012 to the end of trial at 48 weeks

  6. Apparent Clearance (CL)

    Time frame: From pre-dose of YK012 to the end of trial at 48 weeks

  7. Apparent volume of distribution (Vd)

    Time frame: From pre-dose of YK012 to the end of trial at 48 weeks

  8. Minimum Concentration (Cmin) of YK012

    Time frame: From pre-dose of YK012 to the end of trial at 48 weeks

  9. Phase II: Characteristics of peripheral blood B-cell changes

    Time frame: From pre-dose of YK012 to the end of trial at 48 weeks

  10. Change in urinary protein from baseline in patients with positive urinary protein during the trial

    Time frame: From pre-dose of YK012 to the end of trial at 48 weeks

  11. Changes in anti-dsDNA antibody level from baseline

    Time frame: From pre-dose of YK012 to the end of trial at 48 weeks

  12. Changes in complement C3 level from baseline

    Time frame: From pre-dose of YK012 to the end of trial at 48 weeks

  13. Changes in complement C4 level from baseline

    Time frame: From pre-dose of YK012 to the end of trial at 48 weeks

  14. Changes in IgG level from baseline

    Time frame: From pre-dose of YK012 to the end of trial at 48 weeks

  15. Changes in IgM level from baseline

    Time frame: From pre-dose of YK012 to the end of trial at 48 weeks

  16. Changes in IgA levels from baseline

    Time frame: From pre-dose of YK012 to the end of trial at 48 weeks

  17. Anti-Drug Antibody (ADA) positivity rate

    Time frame: From pre-dose of YK012 to the end of trial at 48 weeks

  18. Neutralizing antibody (Nab) positivity rate

    Time frame: From pre-dose of YK012 to the end of trial at 48 weeks

  19. Ib dose escalation stage: Systemic Lupus Erythematosus Responder Index-4 (SRI-4) response rates

    Time frame: From screening to the end of trial at 48 weeks

  20. BILAG-based Composite Lupus Assessment (BICLA) response rates

    Time frame: From screening to the end of trial at 48 weeks

  21. Proportion of patients achieving disease remission as defined by Definition of Remission in SLE (DORIS)

    Time frame: From screening to the end of trial at 48 weeks

  22. Proportion of patients achieving Lupus Low Disease Activity State (LLDAS)

    Time frame: From screening to the end of trial at 48 weeks

  23. Proportion of patients with baseline Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score ≥10 who achieved ≥50% improvement in CLASI (CLASI-50) during the trial

    Time frame: From screening to the end of trial at 48 weeks

  24. Proportion of patients with baseline ≥4 swollen and/or tender joints who achieved ≥50% improvement in joint count during the trial

    Time frame: From screening to the end of trial at 48 weeks

  25. Proportion and duration of patients with baseline glucocorticoid dosage >5mg/day prednisone (or equivalent) achieving dosage ≤5mg/day prednisone (or equivalent)

    Time frame: From screening to the end of trial at 48 weeks

  26. Time to relapse after achieving Lupus Low Disease Activity State (LLDAS) during the trial

    Time frame: From screening to the end of trial at 48 weeks

  27. Change in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score from baseline

    Time frame: From screening to the end of trial at 48 weeks

  28. Change in British Isles Lupus Assessment Group 2004 (BILAG-2004) score from baseline

    Time frame: From screening to the end of trial at 48 weeks

  29. Change in Physician's Global Assessment (PGA) score from baseline

    Time frame: From screening to the end of trial at 48 weeks

  30. Change in 36-Item Short Form Health Survey (SF-36) score from baseline

    Time frame: From screening to the end of trial at 48 weeks

  31. Change in Fatigue Severity Scale (FSS) score from baseline

    Time frame: From screening to the end of trial at 48 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jun 2027, 22 months after the start.

Of 37 phase 1/2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 60. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2025
First posted
Jun 8, 2025
StartActual
Aug 25, 2025
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2028
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07010835
Lead sponsor
Excyte Biopharma Ltd
Responsible party
Sponsor
First posted
Jun 8, 2025
Start date
Aug 25, 2025
Primary completion
Jun 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Feb 5, 2026

Study contacts

Xiaofeng Zeng, Doctor of Medicine
Contact
xiaofeng.zeng@cstar.org.cn
+86 13501069845

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: YK012

Start the discussion